SCHEDULE: Avoro Capital Advisors Discloses Xenon Pharmaceuticals Stake

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported beneficial ownership of 6.26% of Xenon Pharmaceuticals, Inc. common shares as of March 31, 2026.

Summary

• Avoro Capital Advisors LLC, an investment advisory firm, and its controlling person Behzad Aghazadeh have filed a Schedule 13G, indicating their beneficial ownership of Xenon Pharmaceuticals, Inc. common shares.
• The filing reports a total of 5,777,777 shares owned, representing 6.26% of the company's outstanding common shares.
• These shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC.
• The reporting date for this ownership stake is March 31, 2026.
• The total number of outstanding common shares used for the percentage calculation is 92,247,633, reflecting post-offering and full exercise of the underwriters' overallotment option as of March 12, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates significant institutional interest and investment in Xenon Pharmaceuticals, Inc., but does not provide operational or financial performance data for the company itself.

Positives

• Avoro Capital Advisors LLC and Behzad Aghazadeh have taken a significant stake (6.26%) in Xenon Pharmaceuticals, Inc., which could signal confidence in the company's future prospects.
• The acquisition of shares is stated to be for investment purposes, suggesting a long-term view rather than a short-term trading strategy.

Negatives

• The filing does not contain any negative financial results or operational setbacks for Xenon Pharmaceuticals, Inc. itself, as it is a disclosure of ownership by a third party.

Risks

• As with any investment, there is a risk that the value of Xenon Pharmaceuticals, Inc. common shares could decline, impacting the investment held by Avoro Capital Advisors LLC and Behzad Aghazadeh.
• The filing does not explicitly detail specific risks related to Xenon Pharmaceuticals, Inc.'s business operations, but general market and company-specific risks inherent in the pharmaceutical industry would apply.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Xenon Pharmaceuticals, Inc. The future outlook for the investment depends on the performance of Xenon Pharmaceuticals, Inc.

Management Comments

• The filing should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.
• Securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Avoro Capital Advisors LLC and Behzad Aghazadeh indicates a significant institutional investment in Xenon Pharmaceuticals, Inc. This type of filing often suggests that the reporting persons see value and potential growth in the company's pipeline or market position within the competitive biotechnology and pharmaceutical sector.

Stakeholder Impact

• Shareholders of Xenon Pharmaceuticals, Inc.: The increased institutional interest may be viewed positively, potentially leading to increased liquidity and market attention for the stock.
• Avoro Capital Advisors LLC and Behzad Aghazadeh: As significant beneficial owners, their investment performance is directly tied to the success of Xenon Pharmaceuticals, Inc.

Next Steps

• Avoro Capital Advisors LLC and Behzad Aghazadeh will continue to hold the reported shares for investment purposes.
• Further filings may be required if their beneficial ownership stake changes significantly.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership by an investment firm and its principal, not an operational or financial update from Xenon Pharmaceuticals, Inc. While the significant stake suggests confidence, it does not provide enough information to warrant a buy or sell recommendation. Investors should conduct their own due diligence on Xenon Pharmaceuticals, Inc.'s fundamentals.

Keywords

Xenon Pharmaceuticals, Schedule 13G, Avoro Capital Advisors, Behzad Aghazadeh, beneficial ownership, investment, common shares, SEC filing, pharmaceuticals